Last Update: 12-31-1969

Number of Stocks:
Number of New Stocks:

Total Value: $0 Mil
Q/Q Turnover: %

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

' s Profile & Performance

Profile

Total Holding History

Top Ranked Articles

5 Scholarly Articles to Validate Your Value Investment Bias A breakdown of 5 finance papers that will reaffirm a value investor's inclination
Let’s admit it. As value investors, we all have a value investment bias. In fact, all investors are biased toward their preferred approach. Read more...
The Coming Fed-Induced Pension Bust – John Hussman The latest view from the guru
Last week, I observed that, based on the most reliable measures we identify (those having the strongest correlation with actual subsequent 10- to 12-year investment returns across history as well as in recent cycles), “the expected return on a traditional portfolio mix is actually lower at present than at any point in history except the 1929 and 1937 market peaks. QE has effectively front loaded realized past returns while destroying the future return prospects of conventional portfolios, at least as measured from current valuations. As a result, the coming years are likely to see a major pension crisis across both corporations and municipalities because the illusory front loading of returns has encouraged profound underfunding.” Read more...
Louis Moore Bacon Acquires 574,503 Shares of Bunge Company is trading below its intrinsic value with multiple good signs
Louis Moore Bacon invested in a 574,503-share stake in Bunge Ltd. (NYSE:BG) in the first quarter. Read more...
Zeke Ashton Purchases Stake in Dave & Buster's Company has expanded its operations and has multiple streams of income
Guru Zeke Ashton (Trades, Portfolio) purchased a 45,000-share stake in Dave & Buster's Entertainment Inc. (NASDAQ:PLAY) in the first quarter. Read more...
Market Indexes Lower as Market Considers Outlook Bayer one of most actively traded stocks after announcing bid for Monsanto
U.S. market indexes were lower Monday to start the week as investors considered the future outlook with few market catalysts affecting trading for the day. Read more...
» More Articles

Commentaries and Stories

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

The Investors’ Dilemma: Why 2016 May Be a Turning Point - Brandes Investment Funds On 'short-termism' by Barry Gillman, CFA Charles Brandes - The Investors’ Dilemma: Why 2016 May Be A Turning Point - Brandes Investment Funds
Many institutional investors ostensibly support the idea of focusing on long-term horizons. “Short-termism” suggests speculation, with exposure to the randomness of volatile markets. For institutions, the investors’ dilemma is that their obligations are long term but regulatory and behavioral pressures increasingly exert short-term influences on their decisions. Institutional funds and their investment managers are stewards of the capital entrusted to them, with liabilities that may have a multi-decade or even a multi-generational time horizon. They must maintain a long-term perspective. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

JetBlue's Underserving Selloff Is a Buying Opportunity Increasing profits and smart expansion should help JetBlue reverse its situation  - JetBlue's Underserving Selloff Is A Buying Opportunity
Airline stocks have retracted as of late, and the pullback has created a few buying opportunities. Despite the fact that crude oil is still 60% lower than its 2014 highs, airline stocks have retracted due to a weak unit revenue environment. More...

LONG


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

5 Scholarly Articles to Validate Your Value Investment Bias A breakdown of 5 finance papers that will reaffirm a value investor's inclination  - 5 Scholarly Articles To Validate Your Value Investment Bias
Let’s admit it. As value investors, we all have a value investment bias. In fact, all investors are biased toward their preferred approach. More...

DE BONDT & THALER, FAMA & FRENCH, FOERSTER, LSV, VALUE INVESTING, CONFIRMATION BIAS


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Jim Grant Discusses the Forgotten Depression of 1921 With Google Talks Jim Grant tells the tell of how the 1921 recession was cured  - Jim Grant Discusses The Forgotten Depression Of 1921 With Google Talks
According to Jim Grant brilliant investing is when everyone agrees with you. Just later. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

The Coming Fed-Induced Pension Bust – John Hussman The latest view from the guru John Hussman - The Coming Fed-Induced Pension Bust – John Hussman
Last week, I observed that, based on the most reliable measures we identify (those having the strongest correlation with actual subsequent 10- to 12-year investment returns across history as well as in recent cycles), “the expected return on a traditional portfolio mix is actually lower at present than at any point in history except the 1929 and 1937 market peaks. QE has effectively front loaded realized past returns while destroying the future return prospects of conventional portfolios, at least as measured from current valuations. As a result, the coming years are likely to see a major pension crisis across both corporations and municipalities because the illusory front loading of returns has encouraged profound underfunding.” More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

PhaseRX: The Latest Pick From a Legendary VC Firm Following the portfolio movements of ARCH Venture Partners  - PhaseRX: The Latest Pick From A Legendary VC Firm
I became a fan of GuruFocus.com because the website follows the same investing philosophy that I do. We have both concluded that the best way of finding the best investment ideas is by following the best investors. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Should Investors Overlook Amaya's Current Legal Issues? Company's performance looks strong enough to overshadow potential legal penalties  - Should Investors Overlook Amaya's Current Legal Issues?
Amaya (NASDAQ:AYA) is the parent company of Pokerstars, the world’s leading online poker platform. The company reported a strong quarter in the recently released earnings results with significant increments in revenue, net income and EBITDA. More...

DAVID BAAZOV, AMAYA, ONLINE GAMBLING, LONG, INSIDER TRADING


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

This Packaged Foods Company Is a Good Investment B&G Foods is positioned to meet consumers’ needs  - This Packaged Foods Company Is A Good Investment
B&G Foods Inc. (NYSE:BGS) and its subsidiaries manufacture, sell and distribute a diversified portfolio of high-quality, branded shelf-stable foods across the U.S., Canada and Puerto Rico. Based in Parsippany, New Jersey, B&G Foods’ products are marketed under many recognized brands, including Ac’cent, B&G, B&M, Baker’s Joy, Bear Creek Country Kitchens, Brer Rabbit, Canoleo, Cary’s, Cream of Rice, Cream of Wheat, etc. More...

LONG


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

This Restaurant Stock Is Doing Well Kona Grill reported strong 1st quarter with same-store sales growth  - This Restaurant Stock Is Doing Well
Kona Grill (NASDAQ:KONA) offers guests freshly prepared food, personalized service and a warm contemporary ambiance that creates an exceptional, yet affordable dining experience. More...

LONG


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Under Armour Looks Set for Another Run Company's valuation metrics could be misleading given its impressive growth statistics  - Under Armour Looks Set For Another Run
Under Armour (NYSE:UA) is one of the world’s most promising companies in the casual apparel and sportswear market. More...

LONG, GROWTH, UNDER ARMOUR, NIKE, ADIDAS, SPORTSWEAR, APPAREL, FOOTWEAR


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

5 Companies Achieve 52-Week Highs Laboratory Corp., Airgas, Baxalta, Fidelity National Information Services and Zimmer Biomet reach milestones  - 5 Companies Achieve 52-Week Highs
According to GuruFocus' list of 52-week highs, these guru stocks have reached their 52-week highs. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Market Indexes Lower as Market Considers Outlook Bayer one of most actively traded stocks after announcing bid for Monsanto  - Market Indexes Lower As Market Considers Outlook
U.S. market indexes were lower Monday to start the week as investors considered the future outlook with few market catalysts affecting trading for the day. More...

U.S. FINANCIAL MARKET


  • Currently 5.00/5

Rating: 5.0/5 (1 vote)

Bruce Berkowitz Comments on DNOW Guru stock highlight
Supply naturally depletes. Oil and natural gas reserves naturally deplete. Meanwhile, demand for oil and gas will not dissipate; in fact, it increases, especially with the conversion we are seeing to natural gas for utilities. Today, we have a situation where the selling price of these commodities is lower than the price to produce them. This can’t last – something has to give. Demand will go up, and price must rise to entice producers to supply more. When? We don’t know. More...

  • Currently 5.00/5

Rating: 5.0/5 (2 votes)

Value Partners Group: Latest Views on China Market View on China from one of Asia’s largest asset management firms Value Partners Group - Value Partners Group: Latest Views On China Market
The Chinese stockmarket went through a turbulent first quarter of the year with the CSI 300 Index and MSCI China Index declining 13.4% and 4.8% respectively. While it is certain that China’s economy will continue to face headwinds – debt overhang, overcapacity issues and the repositioning of growth away from export and investment – the possibility of a hard landing remains remote. More...

  • Currently 5.00/5

Rating: 5.0/5 (1 vote)

GuruFocus Low P/S Strategies Outperformed By 7% Year-to-Date GuruFocus value strategies outperformed again.  - GuruFocus Low P/S Strategies Outperformed By 7% Year-to-Date
As of today the stock market as measured by S&p 500 is about flat for the year. How is your portfolio doing? More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Louis Moore Bacon Acquires 574,503 Shares of Bunge Company is trading below its intrinsic value with multiple good signs Louis Moore Bacon - Louis Moore Bacon Acquires 574,503 Shares Of Bunge
Louis Moore Bacon invested in a 574,503-share stake in Bunge Ltd. (NYSE:BG) in the first quarter. More...

  • Currently 5.00/5

Rating: 5.0/5 (1 vote)

Baron Funds Comments on Bristol-Myers Squibb Guru stock highlight
After watching and following Bristol-Myers Squibb (NYSE:BMY) for the better part of the last three years we used the weakness in the stock created by the sell-off in the biotech sector to finally initiate a small to medium size position. Bristol specializes in small molecule drugs known as biologics, which are harder for the generic drug companies to replicate, and we are particularly excited about its lead immuno-oncology asset, Opdivo which has shown incredible promise in the treatment of lung cancer, while growing 10-20% month over month since its approval in 2015. Based on our belief in the effectiveness of the PD-1 class drugs, we think there is a high likelihood that Bristol will be able to gain approvals and expand the usage of Opdivo in other types of cancers (melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and could potentially change the paradigm of cancer’s treatment worldwide. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Baron Funds Comments on Illumina Inc. Guru stock highlight
Shares of Illumina, Inc. (NASDAQ:ILMN) detracted from performance in the first quarter. Illumina is the leading provider of DNA sequencing technology to academic and commercial laboratories. Although fourth quarter financial results were solid, management tempered expectations for the first quarter HiSeq X and benchtop instrument sales. We continue to believe Illumina has a long runway for growth, driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Baron Funds Comments on Regeneron Pharmaceuticals Guru stock highlight
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction. More...

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Latest Guru Stock Picks


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK